In this episode, Neil Haley and Tom Quigley dive into one of the hottest workplace health topics of 2025: the rise of GLP-1 weight loss drugs like Ozempic and Wegovy. Are they a breakthrough for employee health—or a financial sinkhole for employer-sponsored plans?

Tom offers a reality check, explaining that these drugs were originally developed for diabetes, not general weight loss. While they’ve gained mainstream popularity, most insurance carriers don’t cover them for non-diabetic purposes—placing employers in a tough spot.

Tom breaks down how ClaimLinx handles employer requests for coverage, the tax-advantaged strategies available for companies that want to help fund them, and how businesses can avoid falling for the hype without harming employee morale or benefits.

• The original purpose of Ozempic and Wegovy: diabetic management, not weight loss

• Why most insurance companies deny coverage for GLP-1s unless tied to diabetes

• How these medications entered the public spotlight as a weight-loss solution

• What employers need to know about rising demand from employees

• Legal ways employers can choose to cover them—if they want to

• Manufacturer rebate programs and alternative sourcing strategies

• Why blindly covering these medications won’t reduce long-term health costs

• Why Tom calls the healthcare system “running with thieves”

• How ClaimLinx guides clients through tough decisions on coverage and cost-benefit

“Ozempic is not a miracle weight-loss drug. It’s a diabetic medication being repurposed—and the insurance companies know it.” — Tom Quigley

“If employers think covering this drug will lower their insurance costs, they’re mistaken. HIPAA prevents you from controlling the risk pool like that.” — Tom Quigley

“You can continue buying insurance the same way you always have… or you can legally pay half and give your team better benefits.” — Tom Quigley

“It's not about saying yes or no to a drug. It's about understanding how to pay for it wisely—if you choose to at all.” — Tom Quigley

• 🚫 Insurance doesn’t cover GLP-1 drugs for weight loss unless the patient is diabetic or pre-diabetic

• ✅ Employers can still fund these meds via Section 105 plans or MERPs—but should do so with clear caps and policies

• 💡 Use manufacturer programs or coupon cards to reduce out-of-pocket costs for employees

• 🔍 Consider the cost-benefit ratio: Does this improve morale and recruitment, or open the door to spiraling costs?

• 🧮 ClaimLinx helps businesses run the math and make data-driven decisions—not emotion-driven ones

• Small & mid-sized business owners

• HR directors and benefits managers

• CFOs concerned with rising healthcare costs

• Brokers and advisors needing clarity on GLP-1 drug coverage

• Employees wondering why Ozempic isn’t covered by their plan

• Website: www.claimlinx.com

• Schedule a Free Consultation: Contact Tom & ClaimLinx

• Related Podcast: Mental Health Coverage & Rising Deductibles

#Ozempic #Wegovy #GLP1Drugs #HealthcareCosts #EmployeeBenefits #ClaimLinx #Section105 #MERP #WeightLossDrugs #EmployerHealthPlans #CuttingEdgeBenefits #NeilHaleyShow #PrescriptionDrugCosts #HealthcareHackathon

🧠 Topics Covered:💬 Notable Quotes:🧰 Practical Takeaways for Employers:🎯 Who This Episode Is For:📍 Resources:📣 Hashtags: